pharma · Advanced Solid Tumor · Sarcoma · PRLD
Prelude Therapeutics
Prelude Therapeutics Inc
Prelude Therapeutics patent portfolio — 16 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 175 Innovation Boulevard, Wilmington, DE 19805, US
- Founded
- 2016
- Employees
- 111
- Programs
- 13
- Drugs
- 5
- Patents
- 16
Prelude Therapeutics patents
16 pharmaceutical patents indexed for Prelude Therapeutics. 0 expire within 24 months.
Prelude Therapeutics has 16 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12414953
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
granted -
US 12129262
CDK inhibitors and their use as pharmaceuticals
granted -
US 11939340
CDK inhibitors and their use as pharmaceuticals
granted -
US 11702423
BRM targeting compounds and associated methods of use
granted -
US 11685744
CDK inhibitors and their use as pharmaceuticals
granted -
US 11673893
CDK inhibitors and their use as pharmaceuticals
granted -
US 11622970
BCL-2 inhibitors and their use as pharmaceuticals
granted -
US 11524962
Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
granted -
US 11254683
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
granted -
US 11220524
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
granted -
US 11214574
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
granted -
US 11208416
Selective inhibitors of protein arginine methytransterase 5 (PRMT5)
granted -
US 11078205
Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)
granted -
US 10711007
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
granted -
US 10570140
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
granted -
US 8957033
Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
granted
Frequently asked questions
How many patents does Prelude Therapeutics have?
16 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Prelude Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.